Opinion|Videos|March 4, 2026
Systemic Therapy and Downstaging in Unresectable, Nonmetastatic HCC
Stephen Lam Chan, MBBS, MD, FRCP, FHKCP, FHKAM, and Gonzalo Cantis, MD, discuss the use of systemic therapy to achieve downstaging in unreeseactable, nonmetastatic HCC.
Advertisement
Episodes in this series
Stephen Lam Chan, MBBS, MD, FRCP, FHKCP, FHKAM, and Gonzalo Cantis, MD, explore the evolving role of systemic therapy as a tool for downstaging disease. Chan reviews how immunotherapy-based combinations may increase the likelihood of tumor shrinkage sufficient to permit resection, transplantation, or ablation in selected patients. Cantis emphasizes careful patient selection and multidisciplinary evaluation when considering downstaging strategies, given variability in liver function and procedural eligibility.
Advertisement
Related to this article
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
New data on multiple targeted agents and evolving diagnostic frameworks highlight progress in classifying and treating EGFR PACC–mutated NSCLC.
Edward B. Garon, MD, MS, details how frontline therapy shapes sequencing in relapsed/refractory EGFR-mutated non–small cell lung cancer.
Five Huntsman Cancer Institute at the University of Utah colleagues earned endowed chair appointments, including new appointments.
The CHMP recommended EU approval of T-DXd plus pertuzumab as first-line therapy for HER2-positive metastatic breast cancer,
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The CHMP has recommended the approval of sacituzumab govitecan/pembrolizumab for treatment-naive, PD-L1-positive metastatic TNBC in the European Union.
Overall survival was the sole US primary end point of the phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab and was not met.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
Dr Akhade on Building the Evidence Base for Low-Dose Immunotherapy
3
Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management
4
Epcoritamab Misses Sole US Primary End Point of Overall Survival in R/R DLBCL
5